| Patient | Paul Robeson |
|---|---|
| Date of birth | 1967-04-09 |
| Identifiers | MRN HR-ML048-SYN; SSN (made up) 000-48-2647 |
| Document date | 2026-06-08 |
| Author | Theodore Bankole-Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of depression treatment. [S]
Mr. Robeson returns three months after starting treatment. He has taken sertraline 200 mg each morning for five weeks, after two weeks at 150 mg, without missing doses and with only mild loose stools. He has attended every weekly behavioral activation session; the psychologist reports PHQ-9 scores in the high teens at each session, with no positive item 9. He walks most days but still has little pleasure, wakes at four, and has not sung or accepted any invitations. He has had no thoughts of suicide. He has had no elation or reduced need for sleep. [S]
| Element | Detail |
|---|---|
| Medicines | Sertraline 200 mg for five weeks after two weeks at 150 mg |
| Therapy | Eleven behavioral activation sessions |
| Mood | PHQ-9 17 from 22 |
| Safety | No thoughts of suicide |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite back; weight 100.2 kg |
| Psychiatric | Positive | Little pleasure, early waking, low drive; no thoughts of suicide; no elation |
| Gastrointestinal | Positive | Mild loose stools on 200 mg |
| Cardiovascular | Negative | No palpitations |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg tablet, one tablet each morning | 50 mg each morning for two weeks | Oral route | 2026-03-12 to 2026-03-25 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning | 100 mg each morning | Oral route | 2026-03-26 to 2026-04-19 | completed | S |
| Sertraline 50 mg tablets, three tablets (150 mg) each morning | 150 mg each morning for two weeks | Oral route | 2026-04-20 to 2026-05-03 | completed | S |
| Sertraline 100 mg tablets, two tablets (200 mg) each morning | 200 mg each morning | Oral route | 2026-05-04 to 2026-06-07 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning for one week, then stop | 100 mg each morning for one week during the switch | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Venlafaxine extended-release 75 mg capsule, one capsule each morning with food | 75 mg each morning for one week | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-08 | Body height | 190 | cm | S |
| 2026-06-08 | Body weight | 100.2 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 74 | /min | S |
| 2026-06-08 | Respiratory rate | 14 | /min | S |
| 2026-06-08 | Body temperature | 36.6 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-08 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 17 | {score} | S |
Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Weight 100.2 kg; blood pressure 128/80, pulse 74 |
| Psychiatric | Slowed; affect constricted; logical; no thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arranged | resolved | confirmed | R53.83 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D). |
| Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview) | active | confirmed | F33.2 | S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted. |
| Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusion | active | confirmed | Z60.5 | S — Synthetic coding of his documented persecution as a social determinant of his depression. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 17, down 23 percent from 22; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Completed today | Rated at each session since the last visit; no positive item 9 reported |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 137 mmol/L, normal |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Adequate trial: five weeks at 200 mg; no response; switch to venlafaxine |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; mild loose stools |
| Medication safety | Switch safety: serotonin syndrome and discontinuation symptoms | During a cross-taper | Completed today | Warning signs explained; sertraline tapered over one week |
| Medication safety | Blood pressure (venlafaxine) | Baseline and at every visit on venlafaxine | Completed today | Baseline 128/80 before venlafaxine |
| Medication safety | Overdose risk and supply | With each prescription | Completed today | 30-day supplies; locked box |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No signs of hypomania |
| Referral | Behavioral activation with a psychologist | Weekly for about sixteen sessions | Completed today | Eleven sessions; activity schedule continuing |
| Medication safety | ECT indications | At each review of a severe episode | Not indicated | No psychosis, refusal of food or drink, or acute suicidal risk; revisit if a second trial fails |
| Referral | Social work for income and costs | Monthly | Completed today | Monthly meetings continue |
Goal progress:
Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse phone check at one week of the switch. Review at about eleven weeks on venlafaxine with the PHQ-9, sodium and blood pressure. Weekly behavioral activation. Call or text 988 at any time in a crisis. Next scheduled visit 2026-08-24: twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECT. [S]